Krystal Biotech (NASDAQ:KRYS) Issues Quarterly Earnings Results, Misses Estimates By $0.17 EPS

Krystal Biotech (NASDAQ:KRYS) announced its quarterly earnings results on Monday. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.20 by ($0.17), Briefing.com reports. The company had revenue of $45.25 million for the quarter, compared to analyst estimates of $47.37 million. During the same quarter last year, the firm posted ($1.76) earnings per share. The business’s quarterly revenue was up 452400.0% compared to the same quarter last year.

Krystal Biotech Stock Up 3.1 %

Shares of KRYS opened at $161.76 on Wednesday. The business’s 50-day moving average price is $168.87 and its 200-day moving average price is $134.11. Krystal Biotech has a twelve month low of $83.38 and a twelve month high of $189.97. The stock has a market cap of $4.61 billion, a PE ratio of 2,022.25 and a beta of 0.91.

Insider Activity at Krystal Biotech

In other news, CAO Kathryn Romano sold 5,000 shares of the business’s stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $165.88, for a total transaction of $829,400.00. Following the completion of the transaction, the chief accounting officer now directly owns 12,936 shares in the company, valued at approximately $2,145,823.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CAO Kathryn Romano sold 5,000 shares of the business’s stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $165.88, for a total transaction of $829,400.00. Following the completion of the transaction, the chief accounting officer now directly owns 12,936 shares in the company, valued at approximately $2,145,823.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $170.96, for a total transaction of $4,274,000.00. Following the transaction, the insider now owns 1,550,882 shares of the company’s stock, valued at $265,138,786.72. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 38,087 shares of company stock valued at $6,210,591. Corporate insiders own 14.10% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Citigroup raised their price target on shares of Krystal Biotech from $160.00 to $195.00 and gave the company a “buy” rating in a research report on Tuesday, February 27th. HC Wainwright reaffirmed a “buy” rating and issued a $200.00 price target on shares of Krystal Biotech in a research report on Monday. William Blair restated an “outperform” rating on shares of Krystal Biotech in a research note on Tuesday, February 27th. Guggenheim upped their target price on Krystal Biotech from $130.00 to $175.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $204.00 price objective (up previously from $178.00) on shares of Krystal Biotech in a research report on Tuesday, April 16th. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Krystal Biotech has an average rating of “Buy” and a consensus target price of $171.00.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).